Abstract
The European defenition of biomarker is done. Global cardiovascular (CV) risk evaluation according the SCORE risk chart, its significance and categorisation in primary prevention of CV disease are explained.
Residual CV risk persists in patients in primary and/or secondary CV prevention, who are treated according to up-to date quidelines. This risk is done by non-LDL dyslipidemia, s.c. atherogenic dyslipidemia.
There are some residual CV risk markers used in Czech patients with stable coronary heart disease, who were enrolled into the EUROASPIRE I-IV studies during the last 16 years. It was atherogenic dyslipidemia (high triglycerides and low HDL-cholesterol plasma levels), hypertriglyceridemic waist and plasma atherogenic index (log of the TG/HDL-cholesterol ratio).
However standard risk factors management was improving, residual CV risk markers were not changing and were more presented in patients with diabetes mellitus.